Authors


Julia Ernst, MS

Latest:

New Stem Cell Therapy May Treat Crohn's Disease

Stem cell transplants may be a new, revolutionary way to treat Crohn's disease.


Linda G. Hughes, MA

Latest:

Stem Cell Therapy Could Stop MS for Many Years, But Funding is an Issue

Experimental stem cell therapy using a patient's own stem cells could offer long-term relief for many patients with multiple sclerosis, though questions still remain regarding cost, patient selection, and efficacy.


Jacquelyn Gray

Latest:

Growth Hormone Therapy Effective at Increasing Anemics' Height During Childhood

For children with Diamond-Blackfan Anemia (DBA) - an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow - growth hormone (GH) therapy was found to increase the short stature of patients - a symptom not widely analyzed.


Querida Anderson, Prachi Patel-Predd

Latest:

The Virtual Window: Clinical Trial Reports--April 2007

The Clinical Trials reported in this issue include: PHASE I: 1) Cell Genesys and Medarex Remain Positive on Combination Immunotherapy Study 2) Active Biotech Achieves Success with TASQ for Prostate Cancer PHASE II: 1) Myriad Initiates Evaluation of Brain Cancer Drug that Crosses the Blood-Brain Barrier 2) Second Lung Cancer Trial Adds Data to Novel Therapy PHASE III: 1) Nexavar Could Soon Add Primary Liver Cancer to its Label 2) Point Therapeutics Provides Clinical Update for NSCLC Studies


Jakob Dupont, MD

Latest:

Jakob Dupont, MD, on ATA188’s Potential in All Forms of Multiple Sclerosis

The global head of research and development at Atara Biotherapeutics discussed ATA188 ahead of anticipated data readouts this month.


Shai Efrati, MD

Latest:

Shai Efrati, MD: Inducing Stem Cell Proliferation With Hyperbaric Oxygen Therapy

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed how hyperbaric oxygen therapy is being used to attempt to improve the damage from neurodegeneration.


Julie Bowen

Latest:

Stem Cell Therapy for Traumatic Brain Injury?

Phase 2 trial results suggest the possibility of a treatment that may regenerate brain cells following TBI.


Spyridoula Vasileiou, PhD

Latest:

Dr. Vasileiou on the Potential Role of ALVR109 for the Treatment of COVID-19

Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109​, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.


Reem Karmali, MD, MS

Latest:

Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCL

Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.


Jason J. Luke, MD

Latest:

Dr. Luke on Future Research With T-Cell Therapy in Melanoma

Jason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma. 


Rachel Narozniak, MA

Latest:

Trial of Triplet Regimen With Cabozantinib Plus Immunotherapy Is Planned in RCC

Investigators see potential in adding targeted therapy to dual immunotherapy for intermediate- and poor-risk patients with renal cell carcinoma. In the phase III COSMIC-313 trial, investigators aim to evaluate cabozantinib, nivolumab, and ipilimumab in patients with untreated advanced RCC.



Denise Myshko

Latest:

CLL1-Targeted CAR T-Cell Therapy Shows Early Promise in Pediatric AML

Results of a phase 1/2 trial show the feasibility of an approach targeting CLL1 in pediatric patients with relapsed or refractory acute myeloid leukemia.


Joshua M. Bauml, MD, Perelman School of Medicine

Latest:

Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCC

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.



David F. McDermott, MD

Latest:

Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCC

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.


Benjamin R. Lee, MD

Latest:

Dr. Lee on Nanotechnology Combination Therapy in RCC

Benjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).



Mary Jo Fidler, MD

Latest:

Dr. Mary Jo Fidler on the Role of Oligoclonal T Cell Expansion in NSCLC

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).


Robert G. Uzzo, MD

Latest:

Dr. Uzzo on Potential of Adjuvant Therapy in Patients With RCC

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).


Robert A. Figlin, MD

Latest:

Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.


Robert Siegel, MD

Latest:

Dr. Siegel Discusses RT-Related AEs for Patients With Oropharyngeal Squamous Cell Carcinomas

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the adverse events (AEs) associated with radiation therapy (RT) for patients with oropharyngeal squamous cell carcinomas.


Dominick Bosse, MD

Latest:

Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).



Wei Z. Ai, MD

Latest:

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.


Ian W. Flinn, MD, PhD

Latest:

Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.


Holger L. Gieschen, MD

Latest:

Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLC

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).


David M. Nanus, MD

Latest:

Dr. Nanus Discusses Adjuvant Therapy for RCC

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.


Sarah B. Goldberg, MD, MPH

Latest:

Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLC

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.


James Larner, MD

Latest:

Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC

James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).

© 2024 MJH Life Sciences

All rights reserved.